Clinical-therapeutic follow-up of patients with American cutaneous leishmaniasis caused by different Leishmania spp. in Brazil

Morais, Rayana Carla Silva de; Melo, Maria Gabriella Nunes de; Goes, Tayná Correia de; Silva, Rômulo Pessoa e; Morais, Rômulo Freire de; Guerra, Jorge Augusto de Oliveira; Brito, Maria Edileuza Felinto de; Brandão-Filho, Sinval Pinto; Paiva-Cavalcanti, Milena de

doi:10.1016/j.exppara.2022.108338

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The conventional therapy for cutaneous and mucocutaneous leishmaniasis in Brazil is meglumine antimoniate (MA) [7], a drug that is difficult to administer and, being highly toxic, can induce severe adverse effects [11][12][13]. Treatment with intravenous liposomal amphotericin B, which is less toxic than MA is recommended for individuals over 50 years of age and those suffering from specific clinical conditions [7], but it is rather expensive [14].…”

Section: Introductionmentioning

confidence: 99%

Temporal patterns, spatial risks, and characteristics of tegumentary leishmaniasis in Brazil in the first twenty years of the 21st Century

et al. 2023

View full text Add to dashboard Cite

Background Tegumentary leishmaniasis (TL) is a significant public health issue in Brazil. The present ecological study describes the clinical and epidemiological characteristics of TL cases reported in the country, and analyzes the spatial and temporal patterns of the incidences and risks of occurrence across the five geopolitical regions and 27 federative units. Methodology/Principal findings Data regarding new cases of TL notified between 2001 and 2020 were obtained from the Information System for Notifiable Diseases of the Brazilian Ministry of Health. Joinpoint and spatial and temporal generalized additive models were used to establish trends in the evolution of TL during the target period. The incidence rate for the entire period was 226.41 cases/100,000 inhabitants. All regions of Brazil showed trends of decreasing incidence rates, albeit with fluctuations at specific times, with the exception of the Southeast where rates have increased since 2014, most particularly in Minas Gerais state. The disease was concentrated predominantly in the North region, with Acre state leading the incidence rank in the whole country, followed by Mato Grosso (Midwest), Maranhão and Bahia (Northeast) states. The spatial distribution of the risk of TL occurrence in relation to the annual averages was relatively stable throughout the period. The cutaneous form of TL was predominant and cases most frequently occurred in rural areas and among men of working age. The ages of individuals contracting TL tended to increase during the time series. Finally, the proportion of confirmations by laboratory tests was lower in the Northeast. Conclusion/Significance TL shows a declining trend in Brazil, but its widespread occurrence and the presence of areas with increasing incidence rates demonstrate the persistent relevance of this disease and the need for constant monitoring. Our findings reinforce the importance of temporal and spatial tools in epidemiologic surveillance routines and are valuable for targeting preventive and control actions.

show abstract

Section: Introductionmentioning

confidence: 99%

Temporal patterns, spatial risks, and characteristics of tegumentary leishmaniasis in Brazil in the first twenty years of the 21st Century

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Of the more than 25 compounds, pentavalent antimonials (Sb5+) are the first-line chemotherapy drugs. Amphotericin B, pentamidine isethionate, miltefosine, and paromomycin are the second-line chemotherapeutics [ 1 , 13 ]. However, the existing drugs are not ideal because of their high toxicity and resistance [ 2 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future

Dinc¹

2022

Korean J Parasitol

View full text Add to dashboard Cite

Leishmaniasis is a serious parasitic disease caused by Leishmania spp. transmitted through sandfly bites. This disease is a major public health concern worldwide. It can occur in 3 different clinical forms: cutaneous, mucocutaneous, and visceral Leishmaniasis (CL, MCL, and VL, respectively), caused by different Leishmania spp. Currently, licensed vaccines are unavailable for the treatment of human Leishmaniasis. The treatment and prevention of this disease rely mainly on chemotherapeutics, which are highly toxic and have an increasing resistance problem. The development of a safe, effective, and affordable vaccine for all forms of vector-borne disease is urgently needed to block transmission of the parasite between the host and vector. Immunological mechanisms in the pathogenesis of Leishmaniasis are complex. IL-12-driven Th1-type immune response plays a crucial role in host protection. The essential purpose of vaccination is to establish a protective immune response. To date, numerous vaccine studies have been conducted using live/attenuated/killed parasites, fractionated parasites, subunits, recombinant or DNA technology, delivery systems, and chimeric peptides. Most of these studies were limited to animals. In addition, standardization has not been achieved in these studies due to the differences in the virulence dynamics of the Leishmania spp. and the feasibility of the adjuvants. More studies are needed to develop a safe and effective vaccine, which is the most promising approach against Leishmania infection.

show abstract

Clinical-therapeutic follow-up of patients with American cutaneous leishmaniasis caused by different Leishmania spp. in Brazil

Cited by 2 publications

References 34 publications

Temporal patterns, spatial risks, and characteristics of tegumentary leishmaniasis in Brazil in the first twenty years of the 21st Century

Temporal patterns, spatial risks, and characteristics of tegumentary leishmaniasis in Brazil in the first twenty years of the 21st Century

Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future

Contact Info

Product

Resources

About